Melbourne, Feb 13, 2009 AEST (ABN Newswire) - Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million). This revision represents an additional A$0.44 million in royalties to Biota.

Contact

Investor / Analyst Enquiries
Biota Holdings Limited
Peter Cook
Tel: +61-3-9915-3720

Damian Lismore
Tel: +61-3-9915-3721



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 6) (Last 30 Days: 37) (Since Published: 7559)